The $200,000 break-up fee is immaterial relative to the company's cash burn and dilutive ATM program. The reacquired rights provide optionality but no near-term revenue catalyst. Monitor for partnership announcements on RHB-102 and the next quarterly filing for cash runway updates.
Price Chart
Executive Summary
RedHill Biopharma regained ex-North America rights to RHB-102 after terminating its license agreement with Hyloris Pharmaceuticals, receiving a $200,000 break-up fee. The company now holds full worldwide rights to the asset and plans to continue late-stage development for oncology support and GI indications, including GLP-1/GIP-associated GI intolerance. This is a minor positive event (reacquired rights + small cash) but does not materially change the company's precarious financial position highlighted by the recent 20-F going-concern warning and ongoing dilutive ATM offering.
Key Facts
- License agreement with Hyloris Pharmaceuticals terminated by mutual agreement effective October 15, 2026
- Hyloris pays RedHill a one-time break-up fee of $200,000
- RedHill regains all ex-North America rights to RHB-102 (once-daily bimodal extended-release ondansetron)
- RedHill now holds full worldwide rights to RHB-102
- Company continues late-stage development for oncology support and GI indications, including GLP-1/GIP-associated GI intolerance
- Company exploring potential partnerships for RHB-102
Financial Impact
Break-up fee of $200,000; no other financial terms disclosed
Risk Factors
- Company faces substantial doubt about going concern per prior 20-F filing with only $4.1M cash
- Ongoing dilutive ATM offering (up to $2.59M additional ADSs) continues to pressure equity
- RHB-102 remains in late-stage development with no approved product revenue timeline
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004808 |
| Document: 0001178913-26-004808-index-headers.html | 0001178913-26-004808 |
| Document: 0001178913-26-004808-index.html | 0001178913-26-004808 |
| Document: 0001178913-26-004808.txt | 0001178913-26-004808 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4230 (−7.03%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 13, 2026 12d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 13, 2026 12d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4230 (−10.76%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4230 (−51.38%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4230 (−53.00%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4230 (−30.08%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4230 (−27.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers